Video | Agriculture | Confidence | Economy | Energy | Employment | Finance | Media | Property | RBNZ | Science | SOEs | Tax | Technology | Telecoms | Tourism | Transport | Search

 


Genesis Announces IPO And Trans Tasman Listing

AUCKLAND, New Zealand – 22 August 2000 – Leading New Zealand Biotechnology company, Genesis Research and Development Corporation Limited, confirmed today that it is proceeding with a NZ$34.5 million initial public share offer and a listing on both the New Zealand Stock Exchange (NZSE) and the Australian Stock Exchange (ASX).

Genesis will offer 5,750,000 shares at an offer price of NZ$6.00, bringing the company’s market capitalisation to approximately NZ$148 million.

The company has registered an investment statement and prospectus for the offer with the New Zealand Companies Office and has also lodged the document with the Australian Securities and Investments Commission. The offer will be open to both institutional and retail investors in New Zealand and Australia.

Announcing the offer, Genesis Founder and CEO, Dr James Watson said the company was well prepared for an IPO in terms of its world-class validated research, a solid product pipeline, strong collaborations and a history of successfully delivering ‘milestones’.

“We look forward to building on the success we have had with a series of successful placements with institutional investors. Having their endorsement creates an extremely favourable platform for the offer.”

Genesis announced in June that six of New Zealand’s leading investors had subscribed for shares as part of a NZ$13.8 million placement. The institutions included Armstrong Jones, Arcus Investment Management, AXA New Zealand Funds Management, BT Funds Management and Guardian Trust Funds Management.

Genesis can now confirm that Corixa Corporation (NASDAQ: CRXA), on behalf of itself and Genesis, has entered into a conditional agreement with Medicis Pharmaceutical Corporation (NYSE: MRX) in relation to the development, commercialisation and licensing of PVAC, the psoriasis treatment that Genesis is developing jointly with Corixa. If the agreement is approved, Medicis Pharmaceutical Corporation will pay a non-refundable payment of US$17 million, additional potential development milestone payments of US$35 million and commercialisation and cumulative net sales threshold milestone payments of US$55 million. Genesis and Corixa Corporation will share any such payments and any subsequent royalty entitlement on commercial sales on a pro-rata basis, after a minority portion of these payments is paid to Stanford Rook Limited for rights in relation to its Mycobacterium vaccae patents.

The offer will see 1.5 million shares reserved for firm allocation to clients of members of the NZSE and ASX as well as a number of other invited financial intermediaries. In addition, 350,000 shares will be reserved for existing shareholders. There will be no public pool.

Dr Watson said most of the money raised by the offer will be applied to Genesis’ research and development activities. “These include the clinical development of our immune therapies for psoriasis and asthma, expansion into eczema, the development of our forestry genomic platform in a relatively new venture with ArborGen LLC and building new databases and technology to secure a foundation in agriculture and horticulture.”

The offer is being managed by UBS Warburg New Zealand Limited and the organising broker is UBS Warburg New Zealand Equities Limited.

The offer is expected to open on Tuesday, 29 August 2000 and close on Thursday, 14 September 2000. Trading on both the NZSE and the ASX is expected to commence on Friday, 22 September. The offer of Genesis shares is contained in the investment statement and prospectus. Anyone wishing to apply for shares in the offer will need to complete the application form that will accompany the investment statement and prospectus.

About Genesis

Genesis is a biotechnology company based in Auckland, New Zealand, with genomic programmes in human health, forestry and agriculture. Genesis builds EST databases that provide the genomic platform for discovery of novel genes with commercial value and has considerable experience and expertise in high-throughput DNA sequencing, functional genomics and development of therapeutics. Partnerships with biopharmaceutical, agricultural, horticultural and forestry companies have been important for funding research to effectively develop potential products. In addition to the extensive forestry gene technology, Genesis has a psoriasis therapeutic, PVACTM, in FDA-approved Phase II clinical trials in partnership with the US-based Corixa Corporation, and a Phase I clinical trial for an asthma therapeutic has been initiated in Wellington, New Zealand.

Application has been made to the New Zealand Stock Exchange for permission to quote the shares and for the listing of Genesis Research and Development Corporation Limited. All the requirements of the NZSE in respect of such quotation and listing that can be complied with on or before the date of the publication of this announcement have been duly complied with. However, the NZSE accepts no responsibility for any statement in this announcement.

ENDS


© Scoop Media

 
 
 
 
 
Business Headlines | Sci-Tech Headlines

 

I Sing The Highway Electric: Charge Net NZ To Connect New Zealand

BMW is turning Middle Earth electric after today announcing a substantial contribution to the charging network Charge Net NZ. This landmark partnership will enable Kiwis to drive their electric vehicles (EVs) right across New Zealand through the installation of a fast charging highway stretching from Kaitaia to Invercargill. More>>

ALSO:

Watch This Space: Mahia Rocket Lab Launch Site Officially Opened

Economic Development Minster Steven Joyce today opened New Zealand’s first orbital launch site, Rocket Lab Launch Complex 1, on the Mahia Peninsula on the North Island’s east coast. More>>

Earlier:

Marketing Rocks!
Ig Nobel Award Winners Assess The Personality Of Rocks

A Massey University marketing lecturer has received the 2016 Ig Nobel Prize for economics for a research project that asked university students to describe the “brand personalities” of three rocks. More>>

ALSO:

Nurofen Promotion: Reckitt Benckiser To Plead Guilty To Misleading Ads

Reckitt Benckiser (New Zealand) intends to plead guilty to charges of misleading consumers over the way it promoted a range of Nurofen products, the Commerce Commission says. More>>

ALSO:

Half A Billion Accounts, Including Xtra: Yahoo Confirms Huge Data Breach

The account information may have included names, email addresses, telephone numbers, dates of birth, hashed passwords (the vast majority with bcrypt) and, in some cases, encrypted or unencrypted security questions and answers. More>>

ALSO:

Rural Branches: Westpac To Close 19 Branches, ANZ Looks At 7

Westpac confirms it will close nineteen branches across the country; ANZ closes its Ngaruawahia branch and is consulting on plans to close six more branches; The bank workers union says many of its members are nervous about their futures and asking ... More>>

Interest Rates: RBNZ's Wheeler Keeps OCR At 2%

Reserve Bank governor Graeme Wheeler kept the official cash rate at 2 percent and said more easing will be needed to get inflation back within the target band. More>>

ALSO:

Get More From Scoop

 
 
 
 
 
 
 
 
 
Business
Search Scoop  
 
 
Powered by Vodafone
NZ independent news